Bioassay Instructions For Tests Using Rats Provided To Bolster US Infant Formula Supply
Executive Summary
Draft details modifications to AOAC International’s PER rat bioassay method to show a formula meets quality factor of sufficient biological quality of protein, one factors FDA considers in evaluating submissions.
You may also be interested in...
US FDA’s Infant Formula Regulatory Authority Doesn’t Reach ‘All That Needs To Be Fixed’
“This system is fundamentally prone to supply chain disruptions with so few manufacturers,” says Mark Moorman, FDA Office of Food Safety director. In FDLI presentation, he acknowledges delicate balance in stemming distribution of potentially contaminated power formula while sustaining supply.
US FDA Notes Concerns At Multiple Formula Plants After One Linked To Contamination, Shortage
Agency sends letters to manufacturers and other businesses involved in production and distribution “to assist industry in improving the microbiological safety of powdered infant formula.” Information from “routine surveillance inspections” of facilities and “for-cause inspections to follow up on consumer complaints” noted in letters.
In Food Programs Restructuring, US FDA Has Designs On Clear Priorities, Chain Of Command
Following reviews prompted largely by formula supply crisis, FDA will move Center for Food Safety and Applied Nutrition and commissioner’s Office of Food Programs and Response to Human Foods Program headed by deputy commissioner. Office of Regulatory Affairs' structure also changing “to support the FDA organization as a whole,” says Commissioner Califf.